Annual Day of the French Network for Rare Skin Disorders

27th November 2020 :  The Annual FIMARAD meeting (French Health Network for Rare Skin Disorders).

 

Core discussions of the day were : Taking stock of the work done in 2020;

 

Issues of the MDPH files (Local House for Disabled People); How to involve Patient representatives;

 

organising the workgroups for 2021;

and ePAGs’ work

See the presentations here

CUTIS LAXA PATIENT JOURNEYS

We have developped 2 patient journeys based on testimonies from our members on what it is like to live with a Cutis Laxa.

Those documents aim to be a tool for health care professionals and patients during a consultation to help them agree on the best possible care on a long term basis.

They will be updated as often as needed to fit with the patients’ daily life and the most recent findings and treatments.

CUTIS LAXA WITH ARTERIES AND LUNGS SYMPTOMS

CUTIS LAXA WITH NEURO AND SKELETON SYMPTOMS

 

6th CUTIS LAXA DAYS

SAVE THE DATES

The 6th Cutis Laxa  Days will be held at the University Hospital of Ghent( Belgium)

on 14th, 15th and 16th September 2022

 

Watch Cecile’s interview

All EPAGS ANNUAL MEETING

5th andt 6th November 2020 : Patient Representatives (ePAG) gathered together, as they do every year, to share improvements, difficulties and successes of their work in the ERNs.

Supported by the Eurordis team, this coming together shines a light on the benefits, but also the gaps, of the organisation of the ERNs.

As Enrique Terol, in charge of Rare Disorders issues at the Health Executive Board in the European Commission, explained, issues linked to gynecology,  pregnancy and family planning are not covered by any of the actual ERNS.

This annual meeting was also the opportunity to gain new knowledge/competencies to improve our work of patient advocacy.

1st Congress of the French Alliance for Rare Disorders

3rd November 2020 :  The first Congress organised by the French Alliance for Rare Disorders gathered together over 250 people. Elected representatives and Healthcare professionnals presented the opportunities, improvements and perspectives for rare disorders for the coming 10 years.

  

 

The subjects of lively workshops were ; Access to diagnosis; Access to treatments and Improving the life journey. To improve patients’ quality of life depends on improving the relationship between local and hospital professionnals.

 

 

WHAT IS AN ERN (European Reference Network) ? (Videos)

Set up 3 years ago by the European Commission, they aim to help patients with rare disorders receive a right diagnosis and follow-up, gather together all European experts and Patients Organisations to allow patients to get the best care.

The European Commission, Patients and ERN Coordinators give their point of view

European Commission (in almost all European Languages)

https://audiovisual.ec.europa.eu/en/video/I-193046

Patients (in English and/or with English subtitles)

https://audiovisual.ec.europa.eu/en/video/I-191813

ERN Coordinators (in English and/or with English subtitles)

https://audiovisual.ec.europa.eu/en/video/I-191812

RARE SKIN DISORDERS AND COVID-19 : An observationnal study

RARE SKIN DISORDERS AND COVID-19

An observational study was initiated by the European Reference Network ERN-Skin and the French Health Network for Rare Skin Disorders (FIMARAD) :

« COVID-19 and rare skin diseases. European observational study (data research) during an epidemic”.

It concerns paediatric and adult patients with rare skin diseases and suspected or confirmed COVID-19 infection who consulted a medical team that is part of the ERN-Skin or FIMARAD. Professor Christine BODEMER (Hôpital Necker-Enfants Malades – Paris, France christine.bodemer@nck.ap-hop-paris.fr ) is the principal investigator..

The main objective of this European observational cohort study (research data) is to determine the impact of a COVID-19 virus infection in a cohort of patients with rare skin diseases and particularly whether these rare diseases and their treatments are risk factors of infection severity

Acquired Cutis Laxa associated with monoclonal gammapathy or multiple myeloma

A possible improvment of the symptoms in Acquired Cutis Laxa associated with monoclonal gammapethy or multiple myeloma:

A haematologist from Sao Paulo (Brasil) has had very satisfactory results in two cases with an autolog bone marrow transplant.

For those two patients the results were more than encouraging though we certainly cannot talk about treatment or cure yet.

Many studies and therapeutic trials are still necessary to get there.

Nevertheless this is a huge leap for those patients

cmgg-Pr Bert CALLEWAERT

RESEARCH ON ACQUIRED CUTIS LAXA

A scientific study on Acquired Cutis Laxa (ACL) is led by

Pr Bert CALLEWAERT

Center for Medical Genetics – Ghent University Hospital

De Pintelaan 185 – B-9000 Gent

Email : Bert.Callewaert@Ugent.be

This type of Cutis Laxa has never been studied before.

It is a great opportunity to learn more about it : how it appears, what are its causes and maybe a first step to treatment.

Worldwide patients with ACL can take part in it. The doors of hope are opening up for them.